Antibacterial medicines – your guide to business trends, R&D and future revenues What’s the future of treatments for human bacterial infections? For those antibiotics you will find new revenue predictions, and analysis exploring research and development. These drugs have substantial sales potential. This study assesses the results, progress, therapies and opportunities.
Visiongain’s new report forecasts those revenues to 2025 at overall world market, submarket, product and national level, discovering what the future holds for drugs treating microbial diseases. This will allow you to stay ahead with definitive market data revealing the market prospects, benefitting your work and authority.
Read on to explore those antimicrobial medicines and their sellers, seeing how high that industry’s sales can go.
Forecasts to 2025 and other analyses explain and predict the vast antibacterials market Why miss the critical business data that you need? Why struggle to find it or fall behind? Instead our investigation shows sales results, market shares, multilevel revenue forecasts and commercial trends to help your decisions and influence.
In particular you will explore product development, seeing agents shaping the future and assessing their potentials. Our study reveals 123 tables, 97 charts and three research interviews with authorities.
And the following sections show how that new survey helps your research, analyses and decisions, helping you stay ahead in knowledge.
Sales predictions for the world antibiotics market and submarkets – see what’s possible What’s that biomedical industry’s potential? What are the secrets of its progress? Discover in our report overall world revenue forecasting to 2025 for those bacteria-treating agents.
Also you will find individual revenue predictions to 2025 for six therapeutic submarkets at world level:
• Cephalosporins • Penicillins • Fluoroquinolones • Macrolides • Carbapenems • Other drug-based therapies for bacterial infections.
You can explore the prospects from 2015, discovering the potentials of novel agents and generic drugs.
Discover where the growing revenue streams are. Hear how companies, patients and healthcare providers can benefit, assessing the most important product classes and companies.
Our study also predicts and discusses leading antibiotics’ revenue potentials.
Predictions for leading and expected products – how will future demand and sales develop? How will individual drugs perform to 2025 at world level? Our survey forecasts revenues of 43 agents – original marketed brands, generic compounds and emerging medicines.
You can assess the top products, including these, seeing what sales they can achieve:
You will discover the medicines and the years with the highest predicted revenues. You can also examine competitors. So discover what’s happening, understanding, challenges, trends and commercial outlooks, including the effects of product obsolescence and rising competition.
For that overall market, the new analysis also shows you geographical revenue predictions.
National markets – high needs worldwide for treating infections drive rising antibiotic demand In developed and developing countries, many opportunities for producers and sellers of bactericidal medicines will occur from 2015. In this study, we reveal where and how, finding what’s possible.
Our work shows you individual revenue forecasts to 2025 for 12 national markets:
• United States (US) • Germany, France, UK, Italy and Spain (EU5 countries) and the overall European Union • China, India, Brazil and Russia (BRIC nations) • South Korea • Japan.
For healing people and saving lives, you can explore the progress, needs and potentials. Find how pharma companies can satisfy those demands for treating bacterial infections. You can also assess the financial potentials from developing, manufacturing and marketing antibiotics.
And what events will change that large, vital medical industry? Our survey shows you, discussing trends, challenges and opportunities.
Market forces and issues – what affects developers, producers and sellers of antibacterials? Our new report explains issues and events affecting that industry and market from 2015, including these influences:
• Antibacterial drug consumption at national level – demand in developed and developing regions and countries • Incidence of pneumonia, community acquired urinary tract infections, bacterial skin disorders and upper respiratory tract infections in leading countries • Generic competition for leading brands – effects of patent expiries and follow on therapies • Prescription control to combat drug-resistant strains and threats from methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) • Drug discovery and development – push and pull incentives, inc. public-private collaborations and other alliances.
And you can explore these forces on the industry, among others:
• R&D pipelines for small-molecule and biological antibacterials (biologics), including monoclonal antibodies (mAbs) and inhaled formulations • Oxazolidinones and other drug classes to stimulate the market • Treating and preventing hospital-acquired infections (HAIs) • Potential for smaller pharma companies to succeed, esp. with partnerships • Guidelines from regulatory bodies and other healthcare policies – effects of changes.
You will discover what the future holds. You can explore the political, economic, social and technological questions. See how R&D lets companies benefit patients and keeps that industry progressing, including overcoming bacterial resistance and serving emerging needs.
You will see what’s possible from 2015 onwards for that industry, its technology and participants.
Analysis of top companies and potential for market growth – what revenue is possible? So what happens next? Our study predicts the world antibacterial drugs market will reach $43.2bn in 2019, with revenue expansion from 2015 to 2025.
In our study discover what drives that commercial expansion. And see what’s possible, in particular by exploring the activities and potentials of these companies:
From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from bacteria-treating drugs. See what the future holds, finding how you can gain.
Ways Antibacterial Drugs: World Industry and Market Prospects 2015-2025 helps In particular, Visiongain’s investigation gives the following information to help your work:
• Revenues for antibacterial drugs to 2025 at world level, for 6 submarkets and 43 medicines – assess the outlook for development, production, marketing and sales
• Forecasts to 2025 for 12 national markets in the Americas, Europe and Asia – investigate the developed and developing countries for potential revenues
• Prospects for established competitors, rising companies and new entrants – explore the portfolios, technologies, results, strategies, R&D and outlooks for success
• Discussions of research and development – see the progress in the industry, finding technological, clinical and commercial outlooks and opportunities
• Opinions from companies and other organisations – discover, through three interviews, views to help you stay ahead in knowledge
• Analysis of what stimulates and restrains that antimicrobial drugs market – assess the challenges and strengths, helping you compete and gain advantage.
This brand new report, by our UK-based analysts, provides knowledge to benefit your research, planning, decisions and proposals. You will find the definitive data leading companies depend on again and again.
Knowledge found nowhere else, helping your work, authority and reputation for insight Our study gives independent data. You will receive competitive intelligence found only in our work, finding where the progress, potential and most lucrative commercial prospects are. You can explore what the future holds.
With this original research and analysis you’re less likely to fall behind in information or miss crucial opportunities. Through your choice now, find how you could save time and effort. This study will benefit your research, analysis and reputation for insight.
This new report of global antibiotic drugs market analysis shows you the potential of medicines for treating human bacterial diseases. You can explore the trends and R&D, also discovering sales forecasts. So avoid missing out in technological and commercial knowledge. You need to purchase this study now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Antibacterial Drugs
2.1 Types of Bacterial Infection
2.2 Main Bacteria Causing Infections in Human Beings
2.3 Incidence and Mortality Profiles for Common Bacterial Infection
2.4 Treating Infections
2.4.1 The History of Antibacterial Drug Development
2.4.2 Mechanisms of Action
2.4.3 Leading Classes of Antibacterial Medicines
2.4.3.1 Cephalosporins
2.4.3.2 Penicillins
2.4.3.3 Carbapenems
2.4.3.4 Fluoroquinolones
2.4.3.5 Macrolides
2.4.4 Antibacterial Drug Resistance
3. Antibacterial Drugs: World Market, 2015-2025
3.1 Antibacterials’ Revenues Plateau between 2009 and 2013
3.2 Antibacterial Agents - Market Segmentation
3.3 Antibiotics Market Forecast, 2015-2025: Decline in Revenues for Fluoroquinolones
3.4 Drivers and Restraints in the Antibacterials Market, 2015-2025
3.5 Generic Erosion and Prescription Control will Limit Market Growth
3.6 Changes in that Industry Sector’s Market Shares, 2015-2025
3.7 Pfizer is the Leader in the Antibacterial Drugs Market
3.8 Fragmented Market to Fracture Further
4. Cephalosporins Market Forecast, 2015-2025
4.1 Cephalosporins Market 2013-2014 – No Dominant Brands
4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2015 and 2025
4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead Cephalosporin Market Between 2015 and 2025
4.1.3 Drivers and Restraints on the Cephalosporins Market, 2015-2025
4.1.4 Cephalosporins Lack Market Exclusivity
4.1.5 Strong Pipeline for Novel Cephalosporins
4.1.6 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.1.6.1 Off Patent but Still Effective
4.1.6.2 Declining Revenues Owing to Competition - Forecast 2015-2025
4.1.7 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2015-2025
4.1.8 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.1.8.1 Continued Decline in Revenue - Forecast 2015-2025
4.1.9 Meiact – A Broad Range Community Antibiotic
4.1.9.1 Spectracef Sales in the US Leads to Pass the Product
4.1.9.2 Competition in Japan to Hinder Growth – Revenue Forecast 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
